没有数据	没有数据

没有数据	没有数据

来源	SDS样本
Syn-Quest	浏览或下载

产品合成路线

更多

名称	CAS号

更多

文章

同行评议文献

Accumulation of BNP7787 in human renal proximal tubule cells.F H Hausheer et al.Journal of pharmaceutical sciences, 100(9), 3977-3984 (2011-02-24) Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.M P Goren et al.Clinical cancer research : an official journal of the American Association for Cancer Research, 4(10), 2313-2320 (1998-10-31) Vibrational spectroscopic studies of mesna and dimesna.Ying-Sing Li et al.Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 59(8), 1791-1798 (2003-05-09) BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.E Boven et al.European journal of cancer (Oxford, England : 1990), 38(8), 1148-1156 (2002-05-15) Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector.Miranda Verschraagen et al.Journal of pharmaceutical sciences, 92(5), 1040-1050 (2003-04-25) Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high performance liquid chromatography.Dakshine Shanmugarajah et al.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 877(10), 857-866 (2009-03-13) Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.Miranda Verschraagen et al.Clinical pharmacology and therapeutics, 74(2), 157-169 (2003-08-02) Supercomputer-designed drug protects against chemotherapy toxicity.K Senior The Lancet. Oncology, 1, 198-198 (2002-03-22) Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.Miranda Verschraagen et al.Cancer chemotherapy and pharmacology, 51(6), 525-529 (2003-05-17) In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna.M J Cutler et al.Journal of clinical pharmacology, 52(4), 530-542 (2011-04-21) The effect of cytoprotective agents in platinum anticancer therapy.Michael A Jakupec et al.Metal ions in biological systems, 42, 179-208 (2004-06-23) New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.Frederick H Hausheer et al.Cancer chemotherapy and pharmacology, 52 Suppl 1, S3-15 (2003-06-24) Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer.Noriyuki Masuda et al.Cancer chemotherapy and pharmacology, 67(3), 533-542 (2010-05-18) Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).Antonius A Miller et al.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 3(10), 1159-1165 (2008-10-02) Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection.M Verschraagen et al.Journal of chromatography. B, Biomedical sciences and applications, 753(2), 293-302 (2001-05-04) Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase.Frederick H Hausheer et al.Cancer chemotherapy and pharmacology, 65(5), 941-951 (2009-08-29) The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG.Miranda Verschraagen et al.Cancer chemotherapy and pharmacology, 51(6), 499-504 (2003-04-26) Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.M Verschraagen et al.British journal of cancer, 90(8), 1654-1659 (2004-04-15) Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N.F H Hausheer et al.Cancer chemotherapy and pharmacology, 67(2), 381-391 (2010-05-05) BNP-7787 (BioNumerik/Baxter Oncology/Grelan).R Todd Reilly IDrugs : the investigational drugs journal, 7(1), 64-69 (2004-01-20) Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.E Boven et al.British journal of cancer, 92(9), 1636-1643 (2005-04-21) Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.Miranda Verschraagen et al.Biochemical pharmacology, 68(3), 493-502 (2004-07-10) BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro.Aulma R Parker et al.Molecular cancer therapeutics, 9(9), 2558-2567 (2010-09-03) Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.Lakshmi Pendyala et al.Cancer chemotherapy and pharmacology, 51(5), 376-384 (2003-04-19) One-step refolding and purification of disulfide-containing proteins with a C-terminal MESNA thioester.Maartje M C Bastings et al.BMC biotechnology, 8, 76-76 (2008-10-03)

备注